Wells Fargo initiated coverage on Inotiv with a new price target
$NOTV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $11.50 → $3.75 | Buy → Hold | Jefferies |
| 2/9/2024 | $3.00 → $11.50 | Hold → Buy | Jefferies |
| 7/20/2023 | $9.00 | Overweight | Wells Fargo |
| 1/19/2023 | $10.00 → $8.00 | Buy → Hold | Jefferies |
| 1/11/2023 | $4.00 → $10.00 | Hold → Buy | Lake Street |
| 11/18/2022 | $60.00 → $7.00 | Buy → Hold | Lake Street |
| 10/4/2022 | $27.00 | Buy | Jefferies |
| 1/31/2022 | $60.00 | Buy | Lake Street |
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
— Enhanced liquidity through issuance of Second Lien Notes — Obtained amendment to credit agreement and extended note payable — Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million — Full year fiscal 2024 revenue down 14.3% to $490.7 million — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2024") and twelve months ("FY 2024") ended Septem
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-267-6316 (Domestic)1-203-518-9783 (In
— Third quarter fiscal 2024 revenue down 32.8% to $105.8 million — Year-to-date fiscal 2024 revenue down 16.5% to $360.3 million — Conclusion of certain government investigations — Site optimization projects complete — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q3 FY 2024") and nine months ("YTD FY 2024") ended June 30, 2024. Revenue by Segment (in millions
424B7 - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
424B5 - Inotiv, Inc. (0000720154) (Filer)
WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock
WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024. The Company intends to use the net proceeds from this offering for working capital,
WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the pricing of its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 900,000 common shares at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously
Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously
Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00
Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti
WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic